- March 10, 2007
Takeda Pharmaceutical Co. warned U.S. doctors
that a study found an increased risk of broken bones in women taking Actos [pioglitazone] for diabetes, less than three weeks after rival GlaxoSmithKline Plc issued a similar precaution for Avandia (rosiglitazone).
[Story at Bloomberg.com:
Takeda Warns of Broken Bones in Women Taking Actos for Diabetes.
The Takeda letter may be found at the FDA's website:
Observation of an Increased Incidence of Fractures in Female Patients
Who Received Long-Term Treatment with ACTOS® (pioglitazone HCL) Tablets for Type 2 Diabetes Mellitus
[PDF file].
The GSK letter may also be found at the FDA's website
Clinical Trial Observation of an Increased
Incidence of Fractures in Female Patients Who Received Long-Term Treatment with Avandia® (rosiglitazone maleate)
Tablets for Type 2 Diabetes Mellitus
[PDF file].]
Advertisement
|
Advertisement
|
- March 4, 2007
The American Diabetes Association (ADA) warned that the diabetes threat was greater than feared.
The number of new cases of
type 2 diabetes
among middle-aged Americans has doubled over the past three decades, fueled largely by increasing rates of obesity, the ADA said.
An estimated two-thirds of adult Americans are now overweight or obese.
The world can now expect many more people to succumb to this chronic disease than originally anticipated, said the organization in a new study:
Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study.
The Lancet 2007; 369:750-756.
[Story at China View;
Abstract at
The Lancet;
full text at
The Lancet,
requires subscription.]
|
|
|
